Companies featured in this edition of the newsletter: ACTC, CVM, CUR, DKAM, ENZ, IMUC, IWEB, PHC, SVUL, SRCO, SVUL, XSNX

Markets extended their winning streak yet again this week, as all ten sectors of the S&P 500 finished in positive territory and markets hit fresh highs for the year once again, despite the lack of any significant developments on either the corporate or economic fronts. All told, the Dow ended up 2.2% on the week, gaining 214 points to close at 9820 on the week, up 11.9% on the year. The Nasdaq performed slightly better, gaining 2.5% on the week, closing at 2132, up 35.2% on the year, while the S&P 500 and Russell 2000 gained 2.5% and 4.1% respectively, up 18.3% and 23.7% on the year.

While it was a relatively quiet week as far as headlines were concerned, there were some positive economic developments in the form

Geron Corp. (Nasdaq: GERN): Stock of the Day

by Katharine Schildt, Assistant Editor, The Oxford Club

A New Era for Stem Cell Research

Stem cell research has been a controversial subject for quite some time. And it’s been no secret that the Bush administration wasn’t a big fan. But just days after President Obama’s inauguration, a huge breakthrough has already been made in the administrative logjam.

Obama officially relaxed the restrictions on federal funding of stem cell research, which has sent shares of this biopharmaceutical company soaring.

Geron Corp. (Nasdaq: GERN), based in the United States, is the premiere developer of biopharmaceuticals for the treatment of certain cancers, as well as degenerative diseases such as spinal cord injury and diabetes.

Already a global leader in the development of embryonic stem cell-based therapies, the U.S. Food and Drug Administration (FDA) has now approved Geron to start the first